Guttate Psoriasis: Small Drop-Like Lesions After Infection

Clinical Overview

Guttate psoriasis is a distinctive variant of psoriasis characterized by sudden onset of numerous small, 1-10 mm diameter papules with a characteristic teardrop or raindrop shape, typically appearing on the trunk and proximal extremities. The condition is frequently (50-90% of cases) preceded by group A streptococcal infection (pharyngitis, impetigo, or other cutaneous infection) by 2-4 weeks, leading to the designation as post-infectious guttate psoriasis. Unlike plaque psoriasis with large, well-demarcated plaques, guttate psoriasis features numerous small lesions distributed across wide body surface area, sometimes affecting 50-100% of body surface area. Guttate psoriasis most frequently affects children and young adults (peak incidence 8-22 years), though it can present at any age. The condition differs prognostically from plaque psoriasis: approximately 50-75% of patients with guttate psoriasis experience spontaneous complete remission within months to years, while others progress to chronic plaque psoriasis. Early recognition of the post-infectious trigger allows potential intervention to prevent progression to chronic disease.

Epidemiology

Guttate psoriasis affects approximately 8-10% of all psoriasis patients, with incidence estimated at 1-3 per 100,000 person-years in Northern European populations. Peak incidence occurs at 8-22 years of age, with some studies showing bimodal distribution with secondary peak in older adults. The condition shows slight female predominance (female-to-male ratio approximately 1.2:1). Preceding group A streptococcal infection is documented in 50-90% of guttate psoriasis cases, with pharyngitis being the most common precursor (occurring in 50-75% of cases with identifiable infection), followed by impetigo and other cutaneous infections. The temporal relationship is typically 2-4 weeks between streptococcal infection and psoriasis onset, though this interval can vary from days to months. Family history of psoriasis is present in approximately 25-40% of patients with guttate psoriasis, indicating genetic predisposition. Geographic variation exists, with higher prevalence in temperate and Northern climates correlating with increased streptococcal pharyngitis incidence during winter months. Seasonal clustering of guttate psoriasis is evident in many populations, with peak incidence in winter months coinciding with peak streptococcal pharyngitis incidence. Patients with guttate psoriasis have improved long-term prognosis compared to those with plaque psoriasis: approximately 50-75% achieve complete clearance of psoriatic lesions within 1-10 years, while 25-50% progress to chronic plaque psoriasis or develop additional psoriasis variants.

Pathophysiology

The pathophysiology of guttate psoriasis involves complex interaction between streptococcal infection, altered immune response, and genetic predisposition. Pathogenic mechanisms appear distinct from plaque psoriasis and may involve molecular mimicry between streptococcal antigens and skin antigens. Group A Streptococcus (GAS) shares epitopes with certain skin antigens, particularly M protein components of GAS showing structural homology with keratins and other skin antigens. Following GAS infection, antibody and T lymphocyte responses directed against GAS antigens may cross-react with structurally similar skin antigens through molecular mimicry mechanism. Streptococcal superantigens (e.g., streptococcal pyrogenic exotoxins) may directly activate T lymphocytes, bypassing normal antigen processing and leading to massive T cell activation and cytokine release. Both mechanisms may contribute to triggering psoriasis development in genetically predisposed individuals. T lymphocyte-mediated immune response with Th1 and Th17 skewing characterizes guttate psoriasis, similar to plaque psoriasis. Th17 cells produce IL-17 and other pro-inflammatory cytokines including IL-22, TNF-α, and IFN-γ, driving keratinocyte activation and recruitment of additional inflammatory cells. Tumor necrosis factor-alpha (TNF-α) pathway activation is central to psoriasis pathogenesis; TNF-α levels are markedly elevated in guttate psoriasis lesional skin and serum. Genetic predisposition is essential for guttate psoriasis development: individuals with genetic susceptibility loci (particularly HLA-C, IL-23 pathway genes, and other psoriasis-associated loci) who encounter streptococcal infection develop guttate psoriasis, while genetically unsusceptible individuals with equivalent GAS infections do not develop psoriasis. Histologically, guttate psoriasis lesions demonstrate features indistinguishable from plaque psoriasis: parakeratosis (retained nuclei in stratum corneum), uniform acanthosis, elongated rete ridges, dilated capillaries in dermal papillae with reduced suprapapillary epidermis, and inflammatory infiltrate with CD8+ T lymphocytes predominating in epidermis and CD4+ T lymphocytes in dermis.

Clinical Presentation

Guttate psoriasis presents acutely with sudden onset of numerous small, 1-10 mm diameter papules with characteristic teardrop or raindrop shape, typically distributed across trunk and proximal extremities (upper back, shoulders, upper arms, thighs). Lesions are erythematous and may show fine scaling or micaceous scale characteristic of psoriasis. The distribution is typically symmetric. Associated pruritus is variable (30-50% of patients) but less prominent than in plaque psoriasis. Some patients report burning or tenderness in lesions. Preceding symptoms of streptococcal infection (pharyngitis, impetigo, or other cutaneous infection) are reported by 50-90% of patients, typically occurring 2-4 weeks before psoriasis onset; some patients may still be experiencing symptoms of active infection when guttate psoriasis develops. Systemic symptoms are typically absent; fever, malaise, or other constitutional symptoms are not features of guttate psoriasis itself, though may be present if concurrent acute streptococcal infection is ongoing. Associated findings may include evidence of recent streptococcal infection including tonsillar enlargement, pharyngeal erythema, or healing impetigo lesions. Body surface area involvement is typically more extensive than in plaque psoriasis: involvement may exceed 50-100% of body surface area at presentation. The acute phase typically persists for weeks to months. Without intervention, approximately 50-75% of patients experience spontaneous resolution within months to years, with complete clearance of psoriatic lesions. Approximately 25-50% of patients develop chronic disease with either persistence of guttate lesions or progression to large plaque psoriasis. Systemic psoriasis manifestations including arthralgia or psoriatic arthritis occur in 5-10% of patients with guttate psoriasis.

Diagnosis

Diagnosis of guttate psoriasis is primarily clinical, based on characteristic presentation of sudden onset of teardrop-shaped lesions in characteristic distribution in a patient with or recent history of streptococcal infection. Key diagnostic criteria include: (1) sudden onset of 1-10 mm diameter papules; (2) characteristic teardrop or raindrop shape; (3) distribution on trunk and proximal extremities; (4) fine scaling; (5) temporal relationship to streptococcal infection (though not absolute requirement); (6) widespread involvement (often >50% body surface area). Dermoscopy reveals fine scale and prominent capillaries consistent with psoriasis. Skin biopsy confirms psoriasis diagnosis when clinical uncertainty exists, demonstrating parakeratosis, uniform acanthosis, elongated rete ridges, dilated capillaries, and inflammatory infiltrate. Assessment for evidence of recent or current streptococcal infection is important: throat culture to identify group A streptococci, anti-streptococcal serologies (anti-streptolysin O titer, anti-DNase B, anti-hyaluronidase), and clinical examination for signs of active infection or healing cutaneous infection. However, negative streptococcal studies do not exclude post-infectious guttate psoriasis, as streptococcal infection may have resolved before serologic conversion occurs. Differential diagnosis includes: drug eruptions (differentiate by temporal relationship to medication use and resolution upon drug discontinuation), pityriasis rosea (distinguished by herald patch, collarette scale on lesions, and resolution within 6-8 weeks), viral exanthems, secondary syphilis (though pityriasis rosea is more common mimic), and morbilliform drug reactions. For patients with progressive or persistent disease, evaluation for psoriatic arthropathy through physical examination and potentially imaging (hands/feet X-rays) may be appropriate.

Treatment Algorithm

Treatment of guttate psoriasis addresses both the acute psoriatic lesions and any ongoing streptococcal infection. In patients with documented recent group A streptococcal infection or evidence of continuing infection, antibiotic therapy is warranted to eliminate the bacterial trigger and potentially prevent progression to chronic psoriasis.

Streptococcal eradication is the first treatment priority if streptococcal infection is identified or strongly suspected. Penicillin V 250-500 mg orally three to four times daily for 10 days is the standard regimen for streptococcal pharyngitis. For penicillin-allergic patients, first-generation cephalosporins (cephalexin 500 mg four times daily for 10 days) can be used if no severe penicillin allergy history exists, as cross-reactivity is low. For patients with documented penicillin allergy, azithromycin 500 mg once daily for 5 days (or 250 mg daily for 10 days) is an acceptable alternative. After completing antibiotic course, repeat throat culture should be obtained in high-risk patients to confirm streptococcal eradication. Some evidence suggests that intensive streptococcal eradication may reduce risk of progression from guttate to chronic plaque psoriasis, though this remains an area of ongoing research.

For acute widespread guttate psoriasis, systemic corticosteroids may be considered for rapidly progressive or severely symptomatic disease: prednisone 0.5-1.0 mg/kg/day (maximum 60 mg daily) for 2-4 weeks, then gradual taper over 3-4 weeks. However, systemic corticosteroids should be used judiciously in psoriasis given their association with triggering pustular psoriasis transformation upon withdrawal. Therefore, corticosteroids are typically reserved for severe, rapidly progressive disease causing significant functional impairment or psychological distress.

Topical corticosteroids applied to individual lesions or small affected areas provide symptomatic relief: medium-potency agents (triamcinolone acetonide 0.1% cream) applied twice daily to accessible lesions. For widespread disease affecting large body surface area, topical therapy alone is impractical; systemic therapy becomes necessary.

Phototherapy provides excellent efficacy for guttate psoriasis without systemic adverse effects. Narrowband UV-B (NB-UVB) phototherapy 3 times weekly produces clearance in 70-90% of patients within 8-12 weeks. UVA phototherapy (PUVA) with oral psoralen followed by UVA exposure also shows good efficacy. Phototherapy is particularly attractive for guttate psoriasis given the widespread distribution of lesions and the favorable prognosis with spontaneous remission in 50-75% of untreated patients.

Systemic immunosuppressive therapy is reserved for severe, rapidly progressive disease unresponsive to phototherapy or corticosteroids, or for disease persisting beyond initial acute phase. Cyclosporine 2.5-5.0 mg/kg/day is effective but is typically reserved for more severe cases. Acitretin (synthetic retinoid) 0.5-1.0 mg/kg/day produces good efficacy in psoriasis and may be considered; however, it requires careful monitoring and is contraindicated in women of childbearing potential due to teratogenicity. Biologic agents including TNF-α inhibitors (etanercept, infliximab, adalimumab) show excellent efficacy for severe guttate psoriasis (etanercept 50 mg twice weekly, or TNF-α inhibitor alternatives at standard dosing). However, these agents are typically reserved for severe refractory disease given cost and potential adverse effects.

Prognosis

The prognosis of guttate psoriasis is substantially better than plaque psoriasis: approximately 50-75% of patients achieve complete spontaneous remission of psoriatic lesions within 3 months to 2 years, while 25-50% progress to chronic disease with either persistent guttate lesions or development of large plaque psoriasis. Factors influencing prognosis include: successful identification and eradication of streptococcal infection (may reduce progression to chronic disease), early intervention with appropriate therapy, patient age (younger patients show higher remission rates), disease severity at presentation, and genetic predisposition (positive family history of psoriasis correlates with higher risk of progression to chronic disease). Patients with complete clearance of psoriatic lesions have recurrence risk of approximately 10-20% over subsequent 10 years; recurrence may occur with subsequent streptococcal infections. For those who progress to chronic psoriasis, disease severity is typically moderate, with plaque morphology often less severe than primary plaque psoriasis.

When to See a Dermatologist

Initial dermatologic evaluation is recommended for all suspected guttate psoriasis to confirm diagnosis and initiate appropriate therapy. Urgent evaluation is indicated if: (1) extensive disease (>50% body surface area) with significant functional impairment; (2) active streptococcal infection requiring identification; (3) progression is rapid or symptoms are severe. Ongoing specialist care is appropriate if: (1) disease does not respond to initial therapy within 2-4 weeks; (2) systemic therapy is being considered; (3) progression to chronic plaque psoriasis occurs; (4) psoriatic arthropathy develops.

Frequently Asked Questions

Q: Can treating strep throat prevent guttate psoriasis? A: Early treatment of streptococcal infection may reduce risk of developing guttate psoriasis, particularly in genetically predisposed individuals. While infection alone does not cause psoriasis (as most people with strep throat do not develop psoriasis), in susceptible individuals, streptococcal eradication may reduce this risk. For persons with psoriasis history, prompt streptococcal treatment is recommended.

Q: Will guttate psoriasis go away on its own? A: Yes, approximately 50-75% of patients with guttate psoriasis experience spontaneous complete remission within 1-2 years without specific treatment. However, treatment can accelerate clearance and reduce disease burden during the acute phase.

Q: Is guttate psoriasis contagious? A: No, guttate psoriasis is not contagious. The underlying trigger (streptococcal infection) is contagious, but psoriasis itself is a non-infectious inflammatory condition resulting from genetic predisposition and immune dysregulation.

Q: Can guttate psoriasis turn into chronic psoriasis? A: Yes, approximately 25-50% of patients with guttate psoriasis progress to chronic disease with either persistent guttate lesions or development of large plaque psoriasis. Factors increasing progression risk include positive family history and severe initial disease.

References